The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- SGLT-2 Inhibitors Being Submitted for Marketing Authorization; First of 6 APIs Should Debut Next Spring
June 14, 2013
- Daiichi Sankyo Launches Osteoporosis Treatment Pralia
June 13, 2013
- Domestic Sales of OTC Drugs Expected to Reach 607.2 Billion Yen in 2013: Fuji-Keizai
June 13, 2013
- DSP, Shionogi Launch Avapro, Irbetan Tablets 200 mg
June 13, 2013
- Kyorin Launches Pentasa Suppositories
June 12, 2013
- Lenvatinib Add-on Therapy Improves PFS in Melanoma Patients: Eisai
June 12, 2013
- Nearly All Major Drug Makers Introduce Systems to Keep Workers over 60
June 12, 2013
- 6 Antipsychotics in PIII Studies; Flurry of NDA Filings Expected in 2015
June 12, 2013
- Pfizer Japan, Takeda Launch Enbrel New Pen Preparation
June 12, 2013
- Otsuka Chosen by METI as Model Enterprise for Efforts to Ensure Stable Drug Supplies During Emergencies
June 11, 2013
- R&D Operations Start for Diagnostic Products: Alfresa Pharma
June 11, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
June 11, 2013
- Ethical, OTC Drug Sales Up 1.3% and 9.5%: Crecon Report
June 10, 2013
- Bayer to File Eylea for mCNV in Japan Later This Year
June 10, 2013
- Taiho’s TS-1 Non-Inferior to UFT/LV in Resected Colon Cancer Patients: PIII Study
June 7, 2013
- Nichi-Iko Announces Launching of Authorized Generic of Allegra in June; Is Late Launch Part of Sanofi’s Carefully Worked-out Strategy?
June 7, 2013
- Use of Contract MRs on the Rise among Smaller Drug Makers; JCSOA’s Goal of “5,000 CMRs by 2015” May Be Realistic
June 7, 2013
- Zeria, Astellas Launch World’s First FD Treatment
June 6, 2013
- DSP Completes Construction of New Chemical Research Facility in Osaka
June 6, 2013
- AZ Decides Not to Proceed with Regulatory Filings for Novel Oral RA Treatment Fostamatinib
June 6, 2013
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…